From promising hits to development-ready programmes, every decision matters.
Taros Discovery is attending BIO-Europe Fall 2026, taking place from 9–11 November at Koelnmesse in Cologne, Germany.
For biotech and pharmaceutical companies, advancing a promising discovery is rarely straightforward. Finding actionable hits, overcoming developability challenges, and keeping R&D programmes on track require the right scientific expertise at the right time.
At Taros, we combine medicinal chemistry, computational chemistry and CMC insight to help teams advance their assets, address risks earlier and make better use of their discovery resources.
A promising hit is only the starting point. Turning it into a viable lead requires careful optimisation of potency, selectivity, physicochemical properties and synthetic accessibility.
Taros brings chemistry expertise and practical problem-solving to help teams navigate these challenges, supporting:
Hit identification, validation and optimisation
DNA-encoded library (DEL) screening and computational chemistry
Structure–activity relationship (SAR) development
Design–Make–Test–Analyse (DMTA) cycles
Medicinal chemistry and lead optimisation
Complex synthesis and early process development
Our focus is on generating the evidence needed to make informed decisions and move promising programmes forward.
Identifying hits is one challenge. Determining which compounds have genuine potential is another.
Through DEL-enabled hit discovery, computer-aided drug design (CADD) and iterative medicinal chemistry, Taros helps teams explore promising chemical starting points and prioritise compounds for further development.
Potency alone does not make a successful development candidate.
Issues involving solubility, metabolic stability, impurities, synthetic feasibility and other developability factors can affect a programme’s progress.
By considering medicinal chemistry and CMC requirements earlier, Taros helps identify potential obstacles before they become costly development challenges.
Not every promising discovery progresses as expected.
Whether a programme faces challenging chemistry, limited SAR progress or synthetic-route difficulties, Taros can bring a fresh scientific perspective through compound redesign, complex synthesis and alternative chemistry strategies.
At BIO-Europe 2026, we look forward to conversations that go beyond individual services.
For biotech teams working within tight timelines and budgets, the real question is often not simply what can be synthesised, but which scientific decisions will create the greatest value for the programme.
Taros combines chemistry expertise with a collaborative, milestone-driven approach to help partners evaluate options, address technical challenges and allocate R&D resources more effectively.
Our team will be available to discuss drug discovery programmes, scientific challenges and potential R&D partnerships.
Dr. Dimitrios Tzalis
CEO, Taros Discovery
Dr. Arunendra Pathak
Vice President & Head of Chemistry Operations
Whether you are advancing a new asset, evaluating an existing lead series or exploring external chemistry support, we welcome the opportunity to connect.
Event: BIO-Europe Fall 2026
Dates: 9–11 November 2026
Venue: Koelnmesse
Location: Cologne, Germany
Taros Representatives: Dr. Dimitrios Tzalis and Dr. Arunendra Pathak
Official event website: https://informaconnect.com/bioeurope/
Taros supports small-molecule drug discovery through hit identification, medicinal chemistry, hit-to-lead development, lead optimisation, custom synthesis and process development, with access to complementary capabilities through specialist partners.
Yes. Taros provides chemistry and process-development expertise to help evaluate synthetic feasibility, impurity-related risks, developability considerations and potential routes towards further development.
Taros can review the chemistry challenges affecting a programme and explore potential solutions involving SAR analysis, compound redesign, lead optimisation and alternative synthetic approaches.
Dr. Dimitrios Tzalis and Dr. Arunendra Pathak will represent Taros Discovery at BIO-Europe 2026 in Cologne.
Bring us your scientific challenge. Let’s explore the next step together.
Meet the Taros team at BIO-Europe Fall 2026 to discuss how our chemistry expertise could support your drug discovery programme.
Taros Chemicals is a research and development partner supporting companies in performance chemicals, polymers, material science, custom synthesis and process development.
From early molecular and material concepts through route development, optimisation and scale-up, Taros combines chemistry expertise in Europe with pilot and manufacturing capabilities in India.
Our teams support partners looking to develop new materials, improve existing chemistry, investigate alternative feedstocks or translate promising laboratory chemistry into more robust and scalable processes. Get in touch with us!
BIO-Europe Fall 2026: Meet Taros Discovery in Cologne Make Better Drug Discovery Decisions. Earlier. From promising hits to development-ready programmes, every decision matters. Taros Discovery is attending BIO-Europe Fall 2026,
ELRIG Drug Discovery 2026: Taros Discovery in London From Promising Hits Towards Development-Ready Leads Join Taros Discovery at ELRIG Drug Discovery 2026, taking place on 14–15 October 2026 at ExCeL
Renewable Materials Conference 2026: Taros Chemicals in Siegburg Performance Chemicals & Polymers – From R&D to Scale-Up Taros Discovery will attend the Renewable Materials Conference 2026 from 22–24 September in
Nordic Life Science Days 2026 : Taros Chemicals at the German Pavilion Taros will exhibit at Nordic Life Science Days (NLSDays) 2026, taking place on 8–9 September 2026 at Kistamässan
At Taros we regularly perform contract research with an emphasis on the design and synthesis of novel building blocks, intermediates and final compounds for several applications. We pride ourselves on a 20 year track record of success in supporting diverse industries with their chemistry and innovation challenges. Our scientists specialize in organic and organometallic synthesis including polymers, from lab scale to pilot quantities. Taros operates a customer-centric and flexible business model providing our diverse clients with customized innovative discovery chemistry services:
Biotechs simply concentrate on their research and development tasks while our experienced chemists take care of all related synthetic chemistry challenges.
From new release mechanisms in band-aid material to the development of chemistry for innovative dual modes of action to help make use of new imaging techniques (PET).
Innovative display technologies require performance chemicals that allow tomorrow’s visual applications in handheld devices, car interfaces or further intelligent equipment.
Providing innovative but cost efficient early drug discovery services and technologies to our pharma customers is what drives our multidisciplinary scientists at Taros.
From literature research to pilot plant – we deliver sophisticated chemicals with full IP to our customers to help them achieve their product development goals.
Your R&D has a specific idea about how the surface should perform by modulating the coating or the curing? Get in touch with our scientists to discuss your chemistry challenge.
Great academic research often requires industrial backing and excellent synthesis capacities to bring ideas to the market – for many years we have been closing that gap.
Get in touch with us if you’d like to discuss the development of new or the improvement of existing synthetic molecules for fragrances, skin care applications or aroma molecules.
Smarter consumer goods require both improved properties and chemicals that provide an acceptable ecological footprint during their entire life cycle.
